Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia: Experiences from the outcome reduction with an Initial Glargine Intervention trial
Authors' conclusion
In patients with dysglycemia and high cardiovascular risk, increasing SHBG was associated with greater risk of HF hospitalizations independent of testosterone concentrations in men but not in women, suggesting the effects could be mediated through androgen-independent pathways.
Study context
- Population
- Dysglycemic participants at high cardiovascular risk in the Outcome Reduction with an Initial Glargine Intervention trial
- Participants
- 8,401 participants
- Comparison
- Sex hormone-binding globulin (SHBG) per 1 SD increase, men vs women
- Menn = 5,553
- Womenn = 2,848
- Primary endpoint
- HF hospitalizations; HR per 1 SD increase in SHBG, adjusted for age, comorbidities, biochemical data (incl. testosterone) and pharmacological treatment
- Follow-up
- Median 6.2 years
Primary result
As reported in the abstract
HF hospitalizations per 1 SD increase in SHBG
| Group | Value | HR per 1 SD SHBG |
|---|---|---|
| Men | 6.3 % | 1.15 (95 % CI 1.03-1.28; p = 0.011) |
| Women | 4.3 % | 1.15 (95 % CI 0.96-1.39; p = 0.14) |
Value
Men6.3 %
Women4.3 %
HR per 1 SD SHBG
Men1.15 (95 % CI 1.03-1.28; p = 0.011)
Women1.15 (95 % CI 0.96-1.39; p = 0.14)
Original publication
Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia: Experiences from the outcome reduction with an Initial Glargine Intervention trial. Diabetes Res Clin Pract. Published 11 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →